Summary of antibody-drug conjugates for MM
| Name . | Target . | Payload . | Combination . | Trial phase: number of patients (n) . | Response/activity . | Current status (ClinicalTrials.gov) . |
|---|---|---|---|---|---|---|
| Belantamab mafodotin (belamaf) | BCMA | MMAF | Monotherapy28 | Phase 1: n = 35 | ORR 60% | DREAMM-1 (completed) NCT02064387 |
| Phase 2: n = 196 | ORR 31% | DREAMM-2 (completed) NCT03525678 | ||||
| B (Q3W) vs Pd | Phase 3: n = 380 (E) | N/A | DREAMM-3 (recruiting) NCT04162210 | |||
| B (Q3W) + Pemb30 | Phase 1/2: n = 41 | ORR 47% | DREAMM-4 (active, not recruiting) NCT03848845 | |||
| B + novel agent31 | Phase 1/2: n = 464 (E) | ORR 53% with feladilimab | DREAMM-5 (recruiting) NCT04126200 | |||
| B-Vd OR Rd32 | Phase 1/2: n = 152 (E) | ORR 78% in BVd arm | DREAMM-6 (active, not recruiting) NCT03544281 | |||
| B-Pd34 | Phase 1/2: n = 96 (E) | ORR 88.9% | ALGONQUIN (recruiting) NCT03715478 | |||
| B-Rd (transplant-ineligible NDMM) | Phase 1/2: n = 66 (E) | N/A | NCT04808037 (recruiting) | |||
| B-Vd vs D-Vd | Phase 3: n = 575 (E) | N/A | DREAMM-7 (active, not recruiting) NCT04246047 | |||
| B-Pd vs V-Pd | Phase 3: n = 450 (E) | N/A | DREAMM-8 (recruiting) NCT04484623 | |||
| B-VRd (transplant-ineligible NDMM33 | Phase 1: n = 144 (E) | ORR 100% (n = 12) | DREAMM-9 (recruiting) NCT04091126 | |||
| Monotherapy in renal impairment | Phase 1: n = 36 (E) | N/A | DREAMM-12 (recruiting) NCT04398745 | |||
| Monotherapy in liver impairment | Phase 1: n = 28 (E) | N/A | DREAMM-13 (recruiting) NCT04398680 | |||
| Monotherapy (varying doses and schedules) | Phase 2: n = 180 (E) | N/A | DREAMM-14 (recruiting) NCT05064358 | |||
| AMG 224 | BCMA | Mertansine | Monotherapy36 | Phase 1: n = 42 (E) | ORR 27% (3 mg/kg) | NCT02561962 (active, not recruiting) |
| CC 99712 | BCMA | Maytansinoid-like | Monotherapy | Phase 1: n = 160 (E) | N/A | NCT04036461 (recruiting) |
| MEDI2228 | BCMA | PBD | Monotherapy37 | Phase 1: n = 82 | ORR 66% at 0.14 mg/kg | NCT03489525 (completed) |
| Indatuximab ravtansine | CD138 | Maytansinoid DM4 | In combination with R or P | Phase 1/2: n = 64 | ORR 71.7% with R and 70.6% with P | NCT01001442 (completed) |
| Lorvotuzumab mertansine | CD56 | Mertansine | Monotherapy | Phase 1: n = 37 | ORR 5.7% | NCT00346255 (completed) |
| Milatuzumab | CD74 | Doxorubicin | Monotherapy | Phase 1: n = 25 | 26% SD | NCT00421525 (completed) |
| STRO-001 | CD74 | MMAF | Monotherapy | Phase 1: n = N/A | N/A | NCT03424603 (recruiting) |
| DFRF4539A | FcRH5 | MMAE | Monotherapy | Phase 1: n = 39 | ORR 5%; 49% SD | NCT01432353 (completed) |
| SGN-CD48A | CD48 | MMAE | Monotherapy | Phase 1: n = 14 | N/A | NCT03379584 (terminated) |
| ABBV-838 | SLAMF7 | MMAE | Monotherapy | Phase 1/1b: n = 75 | ORR 10.7% | NCT02462525 (terminated) |
| Name . | Target . | Payload . | Combination . | Trial phase: number of patients (n) . | Response/activity . | Current status (ClinicalTrials.gov) . |
|---|---|---|---|---|---|---|
| Belantamab mafodotin (belamaf) | BCMA | MMAF | Monotherapy28 | Phase 1: n = 35 | ORR 60% | DREAMM-1 (completed) NCT02064387 |
| Phase 2: n = 196 | ORR 31% | DREAMM-2 (completed) NCT03525678 | ||||
| B (Q3W) vs Pd | Phase 3: n = 380 (E) | N/A | DREAMM-3 (recruiting) NCT04162210 | |||
| B (Q3W) + Pemb30 | Phase 1/2: n = 41 | ORR 47% | DREAMM-4 (active, not recruiting) NCT03848845 | |||
| B + novel agent31 | Phase 1/2: n = 464 (E) | ORR 53% with feladilimab | DREAMM-5 (recruiting) NCT04126200 | |||
| B-Vd OR Rd32 | Phase 1/2: n = 152 (E) | ORR 78% in BVd arm | DREAMM-6 (active, not recruiting) NCT03544281 | |||
| B-Pd34 | Phase 1/2: n = 96 (E) | ORR 88.9% | ALGONQUIN (recruiting) NCT03715478 | |||
| B-Rd (transplant-ineligible NDMM) | Phase 1/2: n = 66 (E) | N/A | NCT04808037 (recruiting) | |||
| B-Vd vs D-Vd | Phase 3: n = 575 (E) | N/A | DREAMM-7 (active, not recruiting) NCT04246047 | |||
| B-Pd vs V-Pd | Phase 3: n = 450 (E) | N/A | DREAMM-8 (recruiting) NCT04484623 | |||
| B-VRd (transplant-ineligible NDMM33 | Phase 1: n = 144 (E) | ORR 100% (n = 12) | DREAMM-9 (recruiting) NCT04091126 | |||
| Monotherapy in renal impairment | Phase 1: n = 36 (E) | N/A | DREAMM-12 (recruiting) NCT04398745 | |||
| Monotherapy in liver impairment | Phase 1: n = 28 (E) | N/A | DREAMM-13 (recruiting) NCT04398680 | |||
| Monotherapy (varying doses and schedules) | Phase 2: n = 180 (E) | N/A | DREAMM-14 (recruiting) NCT05064358 | |||
| AMG 224 | BCMA | Mertansine | Monotherapy36 | Phase 1: n = 42 (E) | ORR 27% (3 mg/kg) | NCT02561962 (active, not recruiting) |
| CC 99712 | BCMA | Maytansinoid-like | Monotherapy | Phase 1: n = 160 (E) | N/A | NCT04036461 (recruiting) |
| MEDI2228 | BCMA | PBD | Monotherapy37 | Phase 1: n = 82 | ORR 66% at 0.14 mg/kg | NCT03489525 (completed) |
| Indatuximab ravtansine | CD138 | Maytansinoid DM4 | In combination with R or P | Phase 1/2: n = 64 | ORR 71.7% with R and 70.6% with P | NCT01001442 (completed) |
| Lorvotuzumab mertansine | CD56 | Mertansine | Monotherapy | Phase 1: n = 37 | ORR 5.7% | NCT00346255 (completed) |
| Milatuzumab | CD74 | Doxorubicin | Monotherapy | Phase 1: n = 25 | 26% SD | NCT00421525 (completed) |
| STRO-001 | CD74 | MMAF | Monotherapy | Phase 1: n = N/A | N/A | NCT03424603 (recruiting) |
| DFRF4539A | FcRH5 | MMAE | Monotherapy | Phase 1: n = 39 | ORR 5%; 49% SD | NCT01432353 (completed) |
| SGN-CD48A | CD48 | MMAE | Monotherapy | Phase 1: n = 14 | N/A | NCT03379584 (terminated) |
| ABBV-838 | SLAMF7 | MMAE | Monotherapy | Phase 1/1b: n = 75 | ORR 10.7% | NCT02462525 (terminated) |
Note: This list is not exhaustive for all ADCs developed for MM.
B, belantamab; belamaf, belantamab mafodotin; D, daratumumab; d, dexamethasone; E, estimate; MMAE, monomethyl auristatin E; N/A, not available; Pemb, pembrolizumab; P, pomalidomide; Q3W, once every 3 weeks; R, lenalidomide; SD, stable disease; V, bortezomib.